Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.

Pituitary adenylate cyclase-activating polypeptide (PACAP) is an inhibitor of megakaryopoiesis and platelet function. Recently, PACAP deficiency was observed in children with nephrotic syndrome (NS), associated with increased platelet count and aggregability and increased risk of thrombosis. To furt...

Full description

Bibliographic Details
Main Authors: Benedicte Eneman, Mohamed A Elmonem, Lambertus P van den Heuvel, Laleh Khodaparast, Ladan Khodaparast, Chris van Geet, Kathleen Freson, Elena Levtchenko
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5536324?pdf=render
_version_ 1818310225826938880
author Benedicte Eneman
Mohamed A Elmonem
Lambertus P van den Heuvel
Laleh Khodaparast
Ladan Khodaparast
Chris van Geet
Kathleen Freson
Elena Levtchenko
author_facet Benedicte Eneman
Mohamed A Elmonem
Lambertus P van den Heuvel
Laleh Khodaparast
Ladan Khodaparast
Chris van Geet
Kathleen Freson
Elena Levtchenko
author_sort Benedicte Eneman
collection DOAJ
description Pituitary adenylate cyclase-activating polypeptide (PACAP) is an inhibitor of megakaryopoiesis and platelet function. Recently, PACAP deficiency was observed in children with nephrotic syndrome (NS), associated with increased platelet count and aggregability and increased risk of thrombosis. To further study PACAP deficiency in NS, we used transgenic Tg(cd41:EGFP) zebrafish with GFP-labeled thrombocytes. We generated two models for congenital NS, a morpholino injected model targeting nphs1 (nephrin), which is mutated in the Finnish-type congenital NS. The second model was induced by exposure to the nephrotoxic compound adriamycin. Nephrin RNA expression was quantified and zebrafish embryos were live-screened for proteinuria and pericardial edema as evidence of renal impairment. Protein levels of PACAP and its binding-protein ceruloplasmin were measured and GFP-labeled thrombocytes were quantified. We also evaluated the effects of PACAP morpholino injection and the rescue effects of PACAP-38 peptide in both congenital NS models. Nephrin downregulation and pericardial edema were observed in both nephrin morpholino injected and adriamycin exposed congenital NS models. However, PACAP deficiency was demonstrated only in the adriamycin exposed condition. Ceruloplasmin levels and the number of GFP-labeled thrombocytes remained unchanged in both models. PACAP morpholino injections worsened survival rates and the edema phenotype in both congenital NS models while injection with human PACAP-38 could only rescue the adriamycin exposed model. We hereby report, for the first time, PACAP deficiency in a NS zebrafish model as a consequence of adriamycin exposure. However, distinct from the human congenital NS, both zebrafish models retained normal levels of ceruloplasmin and thrombocytes. We further extend the renoprotective effects of the PACAP-38 peptide against adriamycin toxicity in zebrafish.
first_indexed 2024-12-13T07:42:41Z
format Article
id doaj.art-0a13a61eb08a455b8542f1f2ec999d81
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T07:42:41Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-0a13a61eb08a455b8542f1f2ec999d812022-12-21T23:54:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018210010.1371/journal.pone.0182100Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.Benedicte EnemanMohamed A ElmonemLambertus P van den HeuvelLaleh KhodaparastLadan KhodaparastChris van GeetKathleen FresonElena LevtchenkoPituitary adenylate cyclase-activating polypeptide (PACAP) is an inhibitor of megakaryopoiesis and platelet function. Recently, PACAP deficiency was observed in children with nephrotic syndrome (NS), associated with increased platelet count and aggregability and increased risk of thrombosis. To further study PACAP deficiency in NS, we used transgenic Tg(cd41:EGFP) zebrafish with GFP-labeled thrombocytes. We generated two models for congenital NS, a morpholino injected model targeting nphs1 (nephrin), which is mutated in the Finnish-type congenital NS. The second model was induced by exposure to the nephrotoxic compound adriamycin. Nephrin RNA expression was quantified and zebrafish embryos were live-screened for proteinuria and pericardial edema as evidence of renal impairment. Protein levels of PACAP and its binding-protein ceruloplasmin were measured and GFP-labeled thrombocytes were quantified. We also evaluated the effects of PACAP morpholino injection and the rescue effects of PACAP-38 peptide in both congenital NS models. Nephrin downregulation and pericardial edema were observed in both nephrin morpholino injected and adriamycin exposed congenital NS models. However, PACAP deficiency was demonstrated only in the adriamycin exposed condition. Ceruloplasmin levels and the number of GFP-labeled thrombocytes remained unchanged in both models. PACAP morpholino injections worsened survival rates and the edema phenotype in both congenital NS models while injection with human PACAP-38 could only rescue the adriamycin exposed model. We hereby report, for the first time, PACAP deficiency in a NS zebrafish model as a consequence of adriamycin exposure. However, distinct from the human congenital NS, both zebrafish models retained normal levels of ceruloplasmin and thrombocytes. We further extend the renoprotective effects of the PACAP-38 peptide against adriamycin toxicity in zebrafish.http://europepmc.org/articles/PMC5536324?pdf=render
spellingShingle Benedicte Eneman
Mohamed A Elmonem
Lambertus P van den Heuvel
Laleh Khodaparast
Ladan Khodaparast
Chris van Geet
Kathleen Freson
Elena Levtchenko
Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
PLoS ONE
title Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
title_full Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
title_fullStr Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
title_full_unstemmed Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
title_short Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.
title_sort pituitary adenylate cyclase activating polypeptide pacap in zebrafish models of nephrotic syndrome
url http://europepmc.org/articles/PMC5536324?pdf=render
work_keys_str_mv AT benedicteeneman pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT mohamedaelmonem pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT lambertuspvandenheuvel pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT lalehkhodaparast pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT ladankhodaparast pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT chrisvangeet pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT kathleenfreson pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome
AT elenalevtchenko pituitaryadenylatecyclaseactivatingpolypeptidepacapinzebrafishmodelsofnephroticsyndrome